Vericel Corporation (VCEL)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vericel Corporation (VCEL)
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Key Insights
Critical company metrics and information
Share Price
$56.36Market Cap
$2.78 BillionTotal Outstanding Shares
49.36 Million SharesTotal Employees
314Dividend
No dividendIPO Date
February 4, 1997SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.vcel.com
Historical Stock Splits
If you bought 1 share of VCEL before October 16, 2013, you'd have 0.05 shares today.
Execution Date | Split Amount |
---|---|
October 16, 2013 | 1-for-20 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $-13.21 Million |
Net Cash Flow From Operating Activities, Continuing | $46.01 Million |
Net Cash Flow From Financing Activities | $13.25 Million |
Net Cash Flow From Investing Activities | $-72.47 Million |
Net Cash Flow From Operating Activities | $46.01 Million |
Net Cash Flow From Financing Activities, Continuing | $13.25 Million |
Net Cash Flow From Investing Activities, Continuing | $-72.47 Million |
Net Cash Flow | $-13.21 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit | $1.10 Million |
Diluted Average Shares | $48.69 Million |
Gross Profit | $162.12 Million |
Net Income/Loss Available To Common Stockholders, Basic | $3.55 Million |
Selling, General, and Administrative Expenses | $138.57 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Average Shares | $48.69 Million |
Revenues | $226.84 Million |
Costs And Expenses | $222.20 Million |
Net Income/Loss | $3.55 Million |
Nonoperating Income/Loss | $5.88 Million |
Operating Income/Loss | $-1.23 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Cost Of Revenue | $64.73 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations Before Tax | $4.65 Million |
Basic Earnings Per Share | $0.08 |
Operating Expenses | $163.34 Million |
Income/Loss From Continuing Operations After Tax | $3.55 Million |
Research and Development | $24.77 Million |
Net Income/Loss Attributable To Parent | $3.55 Million |
Benefits Costs and Expenses | $222.20 Million |
Diluted Earnings Per Share | $0.08 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Assets | $174.76 Million |
Inventory | $15.76 Million |
Accounts Payable | $20.88 Million |
Liabilities And Equity | $390.40 Million |
Equity | $257.47 Million |
Assets | $390.40 Million |
Equity Attributable To Parent | $257.47 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Noncurrent Assets | $199.88 Million |
Wages | $3.09 Million |
Liabilities | $132.93 Million |
Noncurrent Liabilities | $91.59 Million |
Current Liabilities | $41.35 Million |
Current Assets | $190.52 Million |
Other Current Liabilities | $17.38 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.